Q3 EPS Estimates for Dyne Therapeutics Cut by HC Wainwright

Dyne Therapeutics, Inc. (NASDAQ:DYN) – HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Dyne Therapeutics in a note issued to investors on Monday, August 17th. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($0.98) per share for the quarter, down from their prior estimate of ($0.68). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.37) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($3.82) EPS, FY2027 earnings at ($3.28) EPS, FY2028 earnings at ($1.91) EPS, FY2029 earnings at ($0.49) EPS and FY2030 earnings at $1.28 EPS.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33).

A number of other analysts have also recently commented on DYN. Wall Street Zen cut Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Morgan Stanley decreased their price target on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Finally, Royal Bank Of Canada boosted their price objective on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.42.

Dyne Therapeutics Stock Down 0.6%

Shares of NASDAQ:DYN opened at $26.00 on Wednesday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics has a 52-week low of $11.65 and a 52-week high of $27.31. The stock’s fifty day simple moving average is $23.18 and its 200-day simple moving average is $19.61. The company has a market capitalization of $4.86 billion, a P/E ratio of -7.81 and a beta of 1.07.

Insider Activity at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director owned 428,946 shares of the company’s stock, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner purchased 2,500 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was bought at an average price of $17.48 per share, for a total transaction of $43,700.00. Following the acquisition, the director owned 22,500 shares in the company, valued at $393,300. The trade was a 12.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have purchased 6,500 shares of company stock valued at $114,000 and have sold 4,139,196 shares valued at $99,449,852. Corporate insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DYN. Creative Planning increased its position in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 26.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after purchasing an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC acquired a new position in Dyne Therapeutics in the first quarter worth about $26,000. Caxton Associates LLP grew its stake in Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target, well above the recent trading range. The firm continues to project a potential shift to profitability by 2030, forecasting positive EPS of $1.28, despite near-term losses. HC Wainwright analyst coverage
• Neutral Sentiment: Institutional investors and hedge funds own approximately 96.7% of Dyne’s shares, while several funds recently increased their positions. Broader analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $34.42. Dyne institutional and analyst activity
• Negative Sentiment: HC Wainwright significantly reduced its EPS forecasts across 2026-2030. Estimates now call for losses of $3.82 per share in 2026, $3.28 in 2027, $1.91 in 2028 and $0.49 in 2029. Its Q3 and Q4 2026 loss estimates were also widened to $0.98 and $1.01 per share, respectively. The FY2030 profit forecast was cut from $2.26 to $1.28 per share, suggesting a slower path to profitability. Dyne earnings estimate revisions
• Negative Sentiment: Director Jason Rhodes sold a combined 2.59 million shares for approximately $65.2 million through pre-arranged Rule 10b5-1 plans, reducing his holdings by roughly 83% in one transaction and 36% in another. Although the sales were scheduled in advance, their size may pressure sentiment. Dyne director stock sale
• Negative Sentiment: Dyne previously reported quarterly EPS of negative $1.08, missing the consensus estimate of negative $0.75, reinforcing concerns about ongoing cash burn at the clinical-stage biotechnology company. Dyne quarterly earnings

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.